IL17A and juvenile idiopathic arthritis: Pro-inflammatory cytokine therapeutic blockade targeting IL-6 (tocilizumab) [73], IL-17A (secukinumab) [74] and IL12/23 (ustekinumab) [75], in addition to T-cell costimulatory blockade (abatacept) [76], have subsequently received license for treatment of specific JIA phenotypes (see Table 2).